CN115551509A - 包含craf抑制剂的治疗组合 - Google Patents

包含craf抑制剂的治疗组合 Download PDF

Info

Publication number
CN115551509A
CN115551509A CN202180034241.6A CN202180034241A CN115551509A CN 115551509 A CN115551509 A CN 115551509A CN 202180034241 A CN202180034241 A CN 202180034241A CN 115551509 A CN115551509 A CN 115551509A
Authority
CN
China
Prior art keywords
melanoma
compound
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034241.6A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡波尼格罗
V·库克
U·M·斯坦姆伯格
D·斯图尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN115551509A publication Critical patent/CN115551509A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180034241.6A 2020-05-12 2021-05-11 包含craf抑制剂的治疗组合 Pending CN115551509A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023470P 2020-05-12 2020-05-12
US63/023,470 2020-05-12
PCT/IB2021/054013 WO2021229439A1 (en) 2020-05-12 2021-05-11 Therapeutic combinations comprising a craf inhibitor

Publications (1)

Publication Number Publication Date
CN115551509A true CN115551509A (zh) 2022-12-30

Family

ID=75954158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034241.6A Pending CN115551509A (zh) 2020-05-12 2021-05-11 包含craf抑制剂的治疗组合

Country Status (6)

Country Link
US (1) US20240000789A1 (https=)
EP (1) EP4149472A1 (https=)
JP (1) JP2023525100A (https=)
CN (1) CN115551509A (https=)
TW (1) TW202207942A (https=)
WO (1) WO2021229439A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2024148307A1 (en) * 2023-01-06 2024-07-11 Erasca, Inc. Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211849A2 (en) * 2007-10-10 2010-08-04 E-Therapeutics plc Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
CN104640545A (zh) * 2012-08-17 2015-05-20 霍夫曼-拉罗奇有限公司 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法
CN105530931A (zh) * 2013-07-12 2016-04-27 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
CN108368171A (zh) * 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
CN110494166A (zh) * 2017-05-02 2019-11-22 诺华股份有限公司 组合疗法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
AP2016009099A0 (en) 2013-11-01 2016-03-31 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
EP3340987A1 (en) * 2015-08-28 2018-07-04 Novartis AG Combination of ribociclib and dabrafenib for treating or preventing cancer
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
TW202023556A (zh) * 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
CA3123510A1 (en) * 2018-12-20 2020-06-25 Novartis Ag Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
EP4106756A1 (en) * 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211849A2 (en) * 2007-10-10 2010-08-04 E-Therapeutics plc Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
CN104640545A (zh) * 2012-08-17 2015-05-20 霍夫曼-拉罗奇有限公司 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法
CN105530931A (zh) * 2013-07-12 2016-04-27 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
CN108368171A (zh) * 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
CN110494166A (zh) * 2017-05-02 2019-11-22 诺华股份有限公司 组合疗法

Also Published As

Publication number Publication date
TW202207942A (zh) 2022-03-01
US20240000789A1 (en) 2024-01-04
JP2023525100A (ja) 2023-06-14
WO2021229439A1 (en) 2021-11-18
EP4149472A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
US12011449B2 (en) Therapeutic combinations comprising a c-RAF inhibitor
JP7520189B2 (ja) 組み合わせ療法
CN115551509A (zh) 包含craf抑制剂的治疗组合
US20210260059A1 (en) Mdm2 inhibitors and combinations thereof
US20160129003A1 (en) Pharmaceutical Combinations
US20230226030A1 (en) Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
HK40086978A (zh) 包含craf抑制剂的治疗组合
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
RU2815400C2 (ru) Комбинированная терапия
RU2774612C2 (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk
HK40103009A (en) Combination therapy comprising a raf inhibitor and trametinib
JP2022547311A (ja) 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用
WO2015105822A1 (en) Cancer treatment method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40086978

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20221230

RJ01 Rejection of invention patent application after publication